Endothelial cell dysfunction leading to diabetic nephropathy focus on nitric oxide

Hypertension

Volumn 37, Issue 2 II, 2001, Pages 744-748

  Goligorsky, Michael S ^a   Chen, Jun ^a   Brodsky, Sergey ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Collagen; Diabetes mellitus; Nitric oxide synthase; Plasminogen

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; BRADYKININ; CALCIMYCIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN;

CONFERENCE PAPER; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROANGIOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ALBUMINURIA; ANIMAL; CELL CULTURE; DIABETIC ANGIOPATHY; DOWN REGULATION; ENZYMOLOGY; HYPERGLYCEMIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; VASCULAR ENDOTHELIUM;

ALBUMINURIA; ANIMALS; BRADYKININ; CALCIMYCIN; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0035097045     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.37.2.744     Document Type: Conference Paper

References (45)

1. Nephropathy of type-2 diabetes mellitus
2. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas
3. Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy
4. Significance of tubulointerstitial changes in diabetic renal disease
5. Albuminuria reflects widespread vascular damage: The steno hypothesis
6. Modulation of coronary vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
7. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis
8. Nitric oxide activity in the human coronary circulation: Impact of risk factors for coronary atherosclerosis
9. Future horizons in cardiovascular molecular therapies
10. Endothelial dysfunction: Implications for therapy of cardiovascular diseases
11. Endothelial cell in physiology and in the pathophysiology of vascular disorders
12. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
13. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
14. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism
15. Nitric oxide: An endogenous modulator of leukocyte adhesion
16. Intracellular oxidative stress induced ky nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils
17. Nitric oxide released by platelets inhibits neutrophil β2 integrin function following acute carbon monoxide poisoning
18. S-nitroso-N-acetylpenicillamine reduces leukocyte adhesion to type 1 collagen
19. Nitric oxide decreases cytokine-induced endothelial activation
20. L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis
21. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cells
22. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit milogenesis and proliferation of cultured rat vascular smooth muscle cells
23. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
24. Preglomerular sudanophilia in L-NAME hypertensive rats
25. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
26. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: Evidence for reduced availability of nitric oxide during hyperglycemia
27. Glucose scavenging of NO
28. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat artery
29. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes
30. Nonenzymatic glycosylation and the pathogenesis of diabetic complications
31. Glycosylation products as toxic mediators of diabetic complications
32. Recent progress in advanced glycation end products and diabetic complications
33. Pathogenic effects of advanced glycosylation: Biochemical, biologic and clinical implications for diabetes and aging
34. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
35. Altered proliferation of retinal microvascular cells on glycated matrix
36. Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
37. Nitric oxide in diabetic nephropathy
38. NO in diabetic nephropathy
39. Molecular insights into renal interstitial fibrosis
40. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices
41. Delayed branching of endothelial capillary cords in glycated collagen I is mediated by the early induction of PAI-I
42. Histotypic angiogenesis in vitro: Light microscopic, ultrastructural and radioautographic studies
43. The microvascular extracellular matrix: Developmental changes during angiogenesis in the aortic ring-plasma clot model
44. Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-I genes in diabetes and macroangiopathy
45. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima: Media thickness in non-diabetic individuals